Prescient Therapeutics (ASX:PTX) ROE % Adjusted to Book Value: -10.71% (As of Dec. 2025)


What is Prescient Therapeutics ROE % Adjusted to Book Value?

Prescient Therapeutics ASX:PTX -3.17% ROE % Adjusted to Book Value is -10.71% as of Dec. 2025. The stock has 2 warning signs investors should review.

Prescient Therapeutics's ROE % for the quarter that ended in Dec. 2025 was -56.24%. Prescient Therapeutics's PB Ratio for the quarter that ended in Dec. 2025 was 5.25. Prescient Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -10.71%.

Prescient Therapeutics ROE % Adjusted to Book Value Related Terms

Prescient Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Prescient Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics ROE % Adjusted to Book Value Chart

Prescient Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.43 -4.62 -12.93 -21.57 -15.83

Prescient Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.45 -26.25 -11.05 -22.96 -10.71

ASX:PTX vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Prescient Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prescient Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's ROE % Adjusted to Book Value falls into.


Prescient Therapeutics ROE % Adjusted to Book Value Calculation

Prescient Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-49.72% / 3.14
=-15.83%

Prescient Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-56.24% / 5.25
=-10.71%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -10.71% mean?
Prescient Therapeutics (ASX:PTX) has a ROE % Adjusted to Book Value of -10.71% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Prescient Therapeutics and its competitors.
Is Prescient Therapeutics' ROE % Adjusted to Book Value too high?
Prescient Therapeutics' current ROE % Adjusted to Book Value is -10.71%.
How does Prescient Therapeutics' ROE % Adjusted to Book Value compare to VRTX and REGN?
Prescient Therapeutics' ROE % Adjusted to Book Value of -10.71% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Prescient Therapeutics and its competitors. Prescient Therapeutics's current ROE % Adjusted to Book Value is -10.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (ASX:PTX) has a current ROE % Adjusted to Book Value of -10.71%. The current ROE % Adjusted to Book Value is -10.71%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Prescient Therapeutics (ASX:PTX), the current ROE % Adjusted to Book Value is -10.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.